The DOI matches its Crossref record; 201 of the 201 references it cites were found in a registry or an index.
Targeting immunogenic cell stress and death for cancer therapy
Open accessAbstract
Immunogenic cell death (ICD), which results from insufficient cellular adaptation to specific stressors, occupies a central position in the development of novel anticancer treatments. Several therapeutic strategies to elicit ICD — either as standalone approaches or as means to convert immunologically cold tumours that are insensitive to immunotherapy into hot and immunotherapy-sensitive lesions — are being actively pursued. However, the development of ICD-inducing treatments is hindered by various obstacles. Some of these relate to the intrinsic complexity of cancer cell biology, whereas others arise from the use of conventional therapeutic strategies that were developed according to immune-agnostic principles. Moreover, current discovery platforms for the development of novel ICD inducers suffer from limitations that must be addressed to improve bench-to-bedside translational efforts. An improved appreciation of the conceptual difference between key factors that discriminate distinct forms of cell death will assist the design of clinically viable ICD inducers. Immunogenic cell death (ICD) is crucial for the elicitation of anticancer immune responses by therapy, but the successful development of ICD-inducing treatments is hindered by various obstacles. This Review provides an overview of the core mechanisms of ICD, discusses obstacles to the development of novel ICD modulators and assesses established and innovative therapeutic approaches for ICD induction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Clinical development and potential of photothermal and photodynamic therapies for cancer
Li, X., Lovell, J. F., Yoon, J., & Chen, X. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0410-2 · Cited by 3,456
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216 · cited 1×
“Moreover, both accidental necrosis and ferroptosis are often unable to elicit adaptive immunity 33,34 .”
Self-citationThe Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications
Stockwell, B. R. (2022) · Cell · doi:10.1016/j.cell.2022.06.003 · Cited by 3,056
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Forde, P. M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202170 · Cited by 2,825
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809697 · Cited by 2,798
Dendritic cells in cancer immunology and immunotherapy
Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., & Sancho, D. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0210-z · Cited by 2,574
Levy, J. M. M., Towers, C. G., & Thorburn, A. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.53 · Cited by 2,526
Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008) · Science · doi:10.1126/science.1164206 · Cited by 2,081
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Self-citationAdjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Kelly, R. J., Ajani, J. A., Kuzdzal, J., Zander, T., Van Cutsem, E., Piessen, G., Mendez, G., Feliciano, J., Motoyama, S., Lièvre, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032125 · Cited by 1,827
Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance
Elliott, M. R., Chekeni, F. B., Trampont, P. C., Lazarowski, E. R., Kadl, A., Walk, S. F., Park, D., Woodson, R. I., Ostankovich, M., Sharma, P., et al. (2009) · Nature · doi:10.1038/nature08296 · Cited by 1,654
The integrated stress response: From mechanism to disease
Costa-Mattioli, M., & Walter, P. (2020) · Science · doi:10.1126/science.aat5314 · Cited by 1,617
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Bruni, D., Angell, H. K., & Galon, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0285-7 · Cited by 1,586
Autophagy in major human diseases
Klionsky, D. J., Petroni, G., Amaravadi, R. K., Baehrecke, E. H., Ballabio, A., Boya, P., Bravo‐San Pedro, J. M., Cadwell, K., Cecconi, F., Choi, A. M. K., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108863 · Cited by 1,585
Self-citationMitotic progression following DNA damage enables pattern recognition within micronuclei
Harding, S. M., Benci, J. L., Irianto, J., Discher, D. E., Minn, A. J., & Greenberg, R. A. (2017) · Nature · doi:10.1038/nature23470 · Cited by 1,508
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,490
Gardai, S. J., McPhillips, K. A., Frasch, S. C., Janssen, W. J., Starefeldt, A., Murphy-Ullrich, J. E., Bratton, D. L., Oldenborg, P.-A., Michalak, M., & Henson, P. M. (2005) · Cell · doi:10.1016/j.cell.2005.08.032 · Cited by 1,473
Chalabi, M., Fanchi, L. F., Dijkstra, K. K., Van den Berg, J. G., Aalbers, A. G., Sikorska, K., Lopez-Yurda, M., Grootscholten, C., Beets, G. L., Snaebjornsson, P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0805-8 · Cited by 1,417
Autophagy and autophagy-related pathways in cancer
Debnath, J., Gammoh, N., & Ryan, K. M. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00585-z · Cited by 1,403
Long-term outcomes following CAR T cell therapy: what we know so far
Cappell, K. M., & Kochenderfer, J. N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00754-1 · Cited by 1,382
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377
Self-citationDeath by design: apoptosis, necrosis and autophagy
Edinger, A. L., & Thompson, C. B. (2004) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2004.09.011 · Cited by 1,364
Immunogenic cell stress and death
Kroemer, G., Galassi, C., Zitvogel, L., & Galluzzi, L. (2022) · Nature Immunology · doi:10.1038/s41590-022-01132-2 · Cited by 1,353 · cited 8×
“However, if cell death is induced by infectious pathogens such as viruses and intracellular bacteria, it is in the best interest of the organism to mount innate immune responses connected to the activation of adaptive immune effectors 4 .”
InfluentialSelf-citationImmunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349
Self-citationVincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rébé, C., & Ghiringhelli, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3690 · Cited by 1,245
Ghiringhelli, F., Menard, C., Puig, P. E., Ladoire, S., Roux, S., Martin, F., Solary, E., Le Cesne, A., Zitvogel, L., & Chauffert, B. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0225-8 · Cited by 1,241
Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I
Yamamoto, K., Venida, A., Yano, J., Biancur, D. E., Kakiuchi, M., Gupta, S., Sohn, A. S. W., Mukhopadhyay, S., Lin, E. Y., Parker, S. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2229-5 · Cited by 1,240
Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers
Govindan, R., Ding, L., Griffith, M., Subramanian, J., Dees, N. D., Kanchi, K. L., Maher, C. A., Fulton, R., Fulton, L., Wallis, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.024 · Cited by 1,146
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
Zelenay, S., van der Veen, A. G., Böttcher, J. P., Snelgrove, K. J., Rogers, N., Acton, S. E., Chakravarty, P., Girotti, M. R., Marais, R., Quezada, S. A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.015 · Cited by 1,128
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
Advani, R., Flinn, I., Popplewell, L., Forero, A., Bartlett, N. L., Ghosh, N., Kline, J., Roschewski, M., LaCasce, A., Collins, G. P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1807315 · Cited by 1,126
Pannexin 1 channels mediate ‘find-me’ signal release and membrane permeability during apoptosis
Chekeni, F. B., Elliott, M. R., Sandilos, J. K., Walk, S. F., Kinchen, J. M., Lazarowski, E. R., Armstrong, A. J., Penuela, S., Laird, D. W., Salvesen, G. S., et al. (2010) · Nature · doi:10.1038/nature09413 · Cited by 1,120
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042 · cited 1×
“…the endosomal RNA sensor TLR3 can stimulate the secretion of type I interferon and cytokines downstream thereof such as C-X-C motif chemokine ligand 9 (CXCL9) and CXCL10 from cancer cells succumbing to immunogenic chemotherapy, which ultimately favours T cell recruitment into the tumour bed 56,57 .”
Self-citationNecroptosis in development, inflammation and disease
Weinlich, R., Oberst, A., Beere, H. M., & Green, D. R. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.149 · Cited by 1,016
Apoptotic Caspases Suppress mtDNA-Induced STING-Mediated Type I IFN Production
White, M. J., McArthur, K., Metcalf, D., Lane, R. M., Cambier, J. C., Herold, M. J., van Delft, M. F., Bedoui, S., Lessene, G., Ritchie, M. E., et al. (2014) · Cell · doi:10.1016/j.cell.2014.11.036 · Cited by 983
Voorwerk, L., Slagter, M., Horlings, H. M., Sikorska, K., van de Vijver, K. K., de Maaker, M., Nederlof, I., Kluin, R. J. C., Warren, S., Ong, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0432-4 · Cited by 905
Caspase 3–mediated stimulation of tumor cell repopulation during cancer radiotherapy
Huang, Q., Li, F., Liu, X., Li, W., Shi, W., Liu, F.-F., O'Sullivan, B., He, Z., Peng, Y., Tan, A.-C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2385 · Cited by 886
Inflammatory microenvironment remodelling by tumour cells after radiotherapy
McLaughlin, M., Patin, E. C., Pedersen, M., Wilkins, A., Dillon, M. T., Melcher, A. A., & Harrington, K. J. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0246-1 · Cited by 883
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
Blank, C. U., Rozeman, E. A., Fanchi, L. F., Sikorska, K., van de Wiel, B., Kvistborg, P., Krijgsman, O., van den Braber, M., Philips, D., Broeks, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0198-0 · Cited by 880
The clearance of dead cells by efferocytosis
Boada-Romero, E., Martinez, J., Heckmann, B. L., & Green, D. R. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0232-1 · Cited by 876
DAMPs, PAMPs, and LAMPs in Immunity and Sterile Inflammation
Zindel, J., & Kubes, P. (2020) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012419-032847 · Cited by 856
Recent advances and discoveries in the mechanisms and functions of CAR T cells
Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852
Mechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death
Panaretakis, T., Kepp, O., Brockmeier, U., Tesniere, A., Bjorklund, A., Chapman, D. C., Durchschlag, M., Joza, N., Pierron, G., van Endert, P., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.1 · Cited by 848
Self-citationApoptotic Caspases Prevent the Induction of Type I Interferons by Mitochondrial DNA
Rongvaux, A., Jackson, R., Harman, C. C. D., Li, T., West, A. P., de Zoete, M. R., Wu, Y., Yordy, B., Lakhani, S. A., Kuan, C.-Y., et al. (2014) · Cell · doi:10.1016/j.cell.2014.11.037 · Cited by 847
p53: 800 million years of evolution and 40 years of discovery
Levine, A. J. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0262-1 · Cited by 826
Intratumoral heterogeneity in cancer progression and response to immunotherapy
Vitale, I., Shema, E., Loi, S., & Galluzzi, L. (2021) · Nature Medicine · doi:10.1038/s41591-021-01233-9 · Cited by 826
Self-citationA novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death
Garg, A. D., Krysko, D. V., Verfaillie, T., Kaczmarek, A., Ferreira, G. B., Marysael, T., Rubio, N., Firczuk, M., Mathieu, C., Roebroek, A. J. M., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.497 · Cited by 800 · cited 2×
“Moreover, PKR, PERK and GCN2 have all been mechanistically involved in ICD as driven by various stimuli 53,54 .”
Chao, M. P., Jaiswal, S., Weissman-Tsukamoto, R., Alizadeh, A. A., Gentles, A. J., Volkmer, J., Weiskopf, K., Willingham, S. B., Raveh, T., Park, C. Y., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001375 · Cited by 776
He, B., Gross, M., & Roizman, B. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.3.843 · Cited by 751
Integrating oncolytic viruses in combination cancer immunotherapy
Bommareddy, P. K., Shettigar, M., & Kaufman, H. L. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0014-6 · Cited by 704
Ma, Y., Adjemian, S., Mattarollo, S. R., Yamazaki, T., Aymeric, L., Yang, H., Portela Catani, J. P., Hannani, D., Duret, H., Steegh, K., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.03.003 · Cited by 699
Self-citationLee, N. Y., Ferris, R. L., Psyrri, A., Haddad, R. I., Tahara, M., Bourhis, J., Harrington, K., Chang, P. M.-H., Lin, J.-C., Razaq, M. A., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30737-3 · Cited by 661
Fridman, W. H., Meylan, M., Petitprez, F., Sun, C.-M., Italiano, A., & Sautès-Fridman, C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00619-z · Cited by 657
Gardai, S. J., Xiao, Y.-Q., Dickinson, M., Nick, J. A., Voelker, D. R., Greene, K. E., & Henson, P. M. (2003) · Cell · doi:10.1016/s0092-8674(03)00758-x · Cited by 650
Regulated necrosis: disease relevance and therapeutic opportunities
Conrad, M., Angeli, J. P. F., Vandenabeele, P., & Stockwell, B. R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.6 · Cited by 630
RIPK1 and NF-κB signaling in dying cells determines cross-priming of CD8 + T cells
Yatim, N., Jusforgues-Saklani, H., Orozco, S., Schulz, O., Barreira da Silva, R., Reis e Sousa, C., Green, D. R., Oberst, A., & Albert, M. L. (2015) · Science · doi:10.1126/science.aad0395 · Cited by 622
Therapy with oncolytic viruses: progress and challenges
Shalhout, S. Z., Miller, D. M., Emerick, K. S., & Kaufman, H. L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00719-w · Cited by 584
Xk-Related Protein 8 and CED-8 Promote Phosphatidylserine Exposure in Apoptotic Cells
Suzuki, J., Denning, D. P., Imanishi, E., Horvitz, H. R., & Nagata, S. (2013) · Science · doi:10.1126/science.1236758 · Cited by 569
T cell stemness and dysfunction in tumors are triggered by a common mechanism
Vodnala, S. K., Eil, R., Kishton, R. J., Sukumar, M., Yamamoto, T. N., Ha, N.-H., Lee, P.-H., Shin, M., Patel, S. J., Yu, Z., et al. (2019) · Science · doi:10.1126/science.aau0135 · Cited by 552
Caloric restriction mimetics enhance anticancer immunosurveillance
Pietrocola, F., Pol, J., Vacchelli, E., Rao, S., Enot, D. P., Baracco, E. E., Levesque, S., Castoldi, F., Jacquelot, N., Yamazaki, T., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.016 · Cited by 542 · cited 1×
“For example, bona fide ICD inducers such as mitoxantrone or oxaliplatin can be advantageously combined with autophagy-inducing agents (for example, aspirin, hydroxycitrate or spermidine) to obtain improved tumour control and therapeutic cooperativity with PD1 blockade 106–108 .”
Lim, M., Weller, M., Idbaih, A., Steinbach, J., Finocchiaro, G., Raval, R. R., Ansstas, G., Baehring, J., Taylor, J. W., Honnorat, J., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac116 · Cited by 533
Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity
Efimova, I., Catanzaro, E., Van der Meeren, L., Turubanova, V. D., Hammad, H., Mishchenko, T. A., Vedunova, M. V., Fimognari, C., Bachert, C., Coppieters, F., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001369 · Cited by 520
Omuro, A., Brandes, A. A., Carpentier, A. F., Idbaih, A., Reardon, D. A., Cloughesy, T., Sumrall, A., Baehring, J., van den Bent, M., Bähr, O., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noac099 · Cited by 516
Linking cellular stress responses to systemic homeostasis
Galluzzi, L., Yamazaki, T., & Kroemer, G. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0068-0 · Cited by 515
Self-citationTGFβ is a master regulator of radiation therapy-induced antitumor immunity
Vanpouille-Box, C., Diamond, J. M., Pilones, K. A., Zavadil, J., Babb, J. S., Formenti, S. C., Barcellos-Hoff, M. H., & Demaria, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3511 · Cited by 514
Natural killer cells in antiviral immunity
Björkström, N. K., Strunz, B., & Ljunggren, H.-G. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00558-3 · Cited by 503
López-Otín, C., & Kroemer, G. (2021) · Cell · doi:10.1016/j.cell.2020.11.034 · Cited by 499
Self-citationTherapeutic targeting of the hypoxic tumour microenvironment
Singleton, D. C., Macann, A., & Wilson, W. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00539-4 · Cited by 484
Glucocorticoids promote breast cancer metastasis
Obradović, M. M. S., Hamelin, B., Manevski, N., Couto, J. P., Sethi, A., Coissieux, M.-M., Münst, S., Okamoto, R., Kohler, H., Schmidt, A., et al. (2019) · Nature · doi:10.1038/s41586-019-1019-4 · Cited by 462 · cited 1×
“…used for clinical cancer management but often overlooked for their (in some instances well-known) immunosuppressive effects, such as glucocorticoids 199,200 ; considerably detrimental shifts of the local or systemic TME that result from inappropriate dietary habits 201–203 ; and deteriorations of…”
Drugging the efferocytosis process: concepts and opportunities
Mehrotra, P., & Ravichandran, K. S. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00470-y · Cited by 459 · cited 3×
“Such a silent removal of dying cells, which is referred to as ‘efferocytosis’, actively prevents potentially damaging inflammatory reactions and (auto)immune responses against dead cell antigens 2,3 .”
Lu, J., Liu, X., Liao, Y.-P., Salazar, F., Sun, B., Jiang, W., Chang, C. H., Jiang, J., Wang, X., Wu, A. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01651-9 · Cited by 440
An Immunosurveillance Mechanism Controls Cancer Cell Ploidy
Senovilla, L., Vitale, I., Martins, I., Tailler, M., Pailleret, C., Michaud, M., Galluzzi, L., Adjemian, S., Kepp, O., Niso-Santano, M., et al. (2012) · Science · doi:10.1126/science.1224922 · Cited by 436
Self-citationMigration, maintenance and recall of memory T cells in peripheral tissues
Woodland, D. L., & Kohlmeier, J. E. (2009) · Nature Reviews Immunology · doi:10.1038/nri2496 · Cited by 436
Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death
Menger, L., Vacchelli, E., Adjemian, S., Martins, I., Ma, Y., Shen, S., Yamazaki, T., Sukkurwala, A. Q., Michaud, M., Mignot, G., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003807 · Cited by 423
Self-citationHumanized mouse models for immuno-oncology research
Chuprin, J., Buettner, H., Seedhom, M. O., Greiner, D. L., Keck, J. G., Ishikawa, F., Shultz, L. D., & Brehm, M. A. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00721-2 · Cited by 423
Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity
Wiernicki, B., Maschalidi, S., Pinney, J., Adjemian, S., Vanden Berghe, T., Ravichandran, K. S., & Vandenabeele, P. (2022) · Nature Communications · doi:10.1038/s41467-022-31218-2 · Cited by 420
Fucikova, J., Spisek, R., Kroemer, G., & Galluzzi, L. (2021) · Cell Research · doi:10.1038/s41422-020-0383-9 · Cited by 400
Self-citationAhrens, S., Zelenay, S., Sancho, D., Hanč, P., Kjær, S., Feest, C., Fletcher, G., Durkin, C., Postigo, A., Skehel, M., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.008 · Cited by 398
Spisek, R., Charalambous, A., Mazumder, A., Vesole, D. H., Jagannath, S., & Dhodapkar, M. V. (2007) · Blood · doi:10.1182/blood-2006-10-054221 · Cited by 388
Immunological impact of cell death signaling driven by radiation on the tumor microenvironment
Rodriguez-Ruiz, M. E., Vitale, I., Harrington, K. J., Melero, I., & Galluzzi, L. (2020) · Nature Immunology · doi:10.1038/s41590-019-0561-4 · Cited by 385
Self-citationStress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity
Yang, H., Xia, L., Chen, J., Zhang, S., Martin, V., Li, Q., Lin, S., Chen, J., Calmette, J., Lu, M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0566-4 · Cited by 379
Self-citationReijers, I. L. M., Menzies, A. M., van Akkooi, A. C. J., Versluis, J. M., van den Heuvel, N. M. J., Saw, R. P. M., Pennington, T. E., Kapiteijn, E., van der Veldt, A. A. M., Suijkerbuijk, K. P. M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01851-x · Cited by 377
Acetylation Blocks cGAS Activity and Inhibits Self-DNA-Induced Autoimmunity
Dai, J., Huang, Y.-J., He, X., Zhao, M., Wang, X., Liu, Z.-S., Xue, W., Cai, H., Zhan, X.-Y., Huang, S.-Y., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.016 · Cited by 371
Emerging evidence for adapting radiotherapy to immunotherapy
Galluzzi, L., Aryankalayil, M. J., Coleman, C. N., & Formenti, S. C. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00782-x · Cited by 368
Self-citationNon-Oncogene Addiction and the Stress Phenotype of Cancer Cells
Solimini, N. L., Luo, J., & Elledge, S. J. (2007) · Cell · doi:10.1016/j.cell.2007.09.007 · Cited by 365
Apoptotic cell death in disease—Current understanding of the NCCD 2023
Vitale, I., Pietrocola, F., Guilbaud, E., Aaronson, S. A., Abrams, J. M., Adam, D., Agostini, M., Agostinis, P., Alnemri, E. S., Altucci, L., et al. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01153-w · Cited by 361
Self-citationMitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy
Yamazaki, T., Kirchmair, A., Sato, A., Buqué, A., Rybstein, M., Petroni, G., Bloy, N., Finotello, F., Stafford, L., Navarro Manzano, E., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0751-0 · Cited by 359
WDFY4 is required for cross-presentation in response to viral and tumor antigens
Theisen, D. J., Davidson, J. T., Briseño, C. G., Gargaro, M., Lauron, E. J., Wang, Q., Desai, P., Durai, V., Bagadia, P., Brickner, J. R., et al. (2018) · Science · doi:10.1126/science.aat5030 · Cited by 346
The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs
Diepstraten, S. T., Anderson, M. A., Czabotar, P. E., Lessene, G., Strasser, A., & Kelly, G. L. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00407-4 · Cited by 346
Altorki, N. K., McGraw, T. E., Borczuk, A. C., Saxena, A., Port, J. L., Stiles, B. M., Lee, B. E., Sanfilippo, N. J., Scheff, R. J., Pua, B. B., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00149-2 · Cited by 342
The therapeutic potential of targeting regulated non-apoptotic cell death
Hadian, K., & Stockwell, B. R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00749-8 · Cited by 320
Apoptotic Caspases Suppress Type I Interferon Production via the Cleavage of cGAS, MAVS, and IRF3
Ning, X., Wang, Y., Jing, M., Sha, M., Lv, M., Gao, P., Zhang, R., Huang, X., Feng, J.-M., & Jiang, Z. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.02.013 · Cited by 317
Herbst, R. S., Majem, M., Barlesi, F., Carcereny, E., Chu, Q., Monnet, I., Sanchez-Hernandez, A., Dakhil, S., Camidge, D. R., Winzer, L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00227 · Cited by 304
Crizotinib-induced immunogenic cell death in non-small cell lung cancer
Liu, P., Zhao, L., Pol, J., Levesque, S., Petrazzuolo, A., Pfirschke, C., Engblom, C., Rickelt, S., Yamazaki, T., Iribarren, K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09415-3 · Cited by 302 · cited 3×
“One example is provided by the combination of cisplatin, which is not an optimal ICD driver as it generally fails to elicit the ISR, with an agent capable of correcting such a signalling defect, such as cardiac glycosides or crizotinib 66,102 .”
The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death
Pozzi, C., Cuomo, A., Spadoni, I., Magni, E., Silvola, A., Conte, A., Sigismund, S., Ravenda, P. S., Bonaldi, T., Zampino, M. G., et al. (2016) · Nature Medicine · doi:10.1038/nm.4078 · Cited by 292
Li, J., Liu, J., Zhou, Z., Wu, R., Chen, X., Yu, C., Stockwell, B., Kroemer, G., Kang, R., & Tang, D. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adg3049 · Cited by 275
Self-citationTipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death
Hayashi, K., Nikolos, F., Lee, Y. C., Jain, A., Tsouko, E., Gao, H., Kasabyan, A., Leung, H. E., Osipov, A., Jung, S. Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19970-9 · Cited by 274
Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape
DeSelm, C., Palomba, M. L., Yahalom, J., Hamieh, M., Eyquem, J., Rajasekhar, V. K., & Sadelain, M. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.09.008 · Cited by 273
Garg, A. D., Vandenberk, L., Koks, C., Verschuere, T., Boon, L., Van Gool, S. W., & Agostinis, P. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aae0105 · Cited by 270
Mitochondrial permeabilization engages NF-κB-dependent anti-tumour activity under caspase deficiency
Giampazolias, E., Zunino, B., Dhayade, S., Bock, F., Cloix, C., Cao, K., Roca, A., Lopez, J., Ichim, G., Proïcs, E., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3596 · Cited by 258
Immunomodulation by radiotherapy in tumour control and normal tissue toxicity
Cytlak, U. M., Dyer, D. P., Honeychurch, J., Williams, K. J., Travis, M. A., & Illidge, T. M. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00568-1 · Cited by 258
Trial watch: Oncolytic viruses for cancer therapy
Vacchelli, E., Eggermont, A., Sautès-Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24612 · Cited by 255
Self-citationcGAS/STING axis mediates a topoisomerase II inhibitor–induced tumor immunogenicity
Wang, Z., Chen, J., Hu, J., Zhang, H., Xu, F., He, W., Wang, X., Li, M., Lu, W., Zeng, G., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127471 · Cited by 253 · cited 1×
“…the endosomal RNA sensor TLR3 can stimulate the secretion of type I interferon and cytokines downstream thereof such as C-X-C motif chemokine ligand 9 (CXCL9) and CXCL10 from cancer cells succumbing to immunogenic chemotherapy, which ultimately favours T cell recruitment into the tumour bed 56,57 .”
Zhou, Q., Chen, M., Jiang, O., Pan, Y., Hu, D., Lin, Q., Wu, G., Cui, J., Chang, J., Cheng, Y., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00630-6 · Cited by 244
Spigel, D. R., Reynolds, C., Waterhouse, D., Garon, E. B., Chandler, J., Babu, S., Thurmes, P., Spira, A., Jotte, R., Zhu, J., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.02.022 · Cited by 229
ATP and cancer immunosurveillance
Kepp, O., Bezu, L., Yamazaki, T., Di Virgilio, F., Smyth, M. J., Kroemer, G., & Galluzzi, L. (2021) · The EMBO Journal · doi:10.15252/embj.2021108130 · Cited by 229
Self-citationDesigning Cancer Immunotherapies That Engage T Cells and NK Cells
Kyrysyuk, O., & Wucherpfennig, K. W. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101921-044122 · Cited by 213
Ansell, S. M., Maris, M. B., Lesokhin, A. M., Chen, R. W., Flinn, I. W., Sawas, A., Minden, M. D., Villa, D., Percival, M.-E. M., Advani, A. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3706 · Cited by 205
Endogenous Retroelements and the Viral Mimicry Response in Cancer Therapy and Cellular Homeostasis
Chen, R., Ishak, C. A., & De Carvalho, D. D. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0506 · Cited by 205
Absence of RNase H2 triggers generation of immunogenic micronuclei removed by autophagy
Bartsch, K., Knittler, K., Borowski, C., Rudnik, S., Damme, M., Aden, K., Spehlmann, M. E., Frey, N., Saftig, P., Chalaris, A., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx283 · Cited by 196 · cited 1×
“150,151); by autophagy-dependent degradation of cellular sources of cGAS-activatory DNA species, including permeabilized mitochondria 152 and micronuclei 153,154 ; and through defects in the signal transducers of type I interferon receptors, such as Janus kinase 1 (JAK1) 155 .”
Modulation of regulatory T cell function and stability by co-inhibitory receptors
Lucca, L. E., & Dominguez-Villar, M. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0296-3 · Cited by 189
The NK cell receptor NKp46 recognizes ecto-calreticulin on ER-stressed cells
Sen Santara, S., Lee, D.-J., Crespo, Â., Hu, J. J., Walker, C., Ma, X., Zhang, Y., Chowdhury, S., Meza-Sosa, K. F., Lewandrowski, M., et al. (2023) · Nature · doi:10.1038/s41586-023-05912-0 · Cited by 187
Gomes-Santos, I. L., Amoozgar, Z., Kumar, A. S., Ho, W. W., Roh, K., Talele, N. P., Curtis, H., Kawaguchi, K., Jain, R. K., & Fukumura, D. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0499 · Cited by 181
Immunosurveillance in clinical cancer management
Kroemer, G., Chan, T. A.-T., Eggermont, A. M. M., & Galluzzi, L. (2023) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21818 · Cited by 177
Self-citationDrugging the addict: non‐oncogene addiction as a target for cancer therapy
Nagel, R., Semenova, E. A., & Berns, A. J. M. (2016) · EMBO Reports · doi:10.15252/embr.201643030 · Cited by 175
High hydrostatic pressure induces immunogenic cell death in human tumor cells
Fucikova, J., Moserova, I., Truxova, I., Hermanova, I., Vancurova, I., Partlova, S., Fialova, A., Sojka, L., Cartron, P., Houska, M., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28766 · Cited by 170
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
Choueiri, T. K., Powles, T., Albiges, L., Burotto, M., Szczylik, C., Zurawski, B., Yanez Ruiz, E., Maruzzo, M., Suarez Zaizar, A., Fein, L. E., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212851 · Cited by 164
Immunomodulation by anticancer cell cycle inhibitors
Petroni, G., Formenti, S. C., Chen-Kiang, S., & Galluzzi, L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0300-y · Cited by 163 · cited 1×
“Although such therapeutic assays are closer to clinical reality than prophylactic vaccination assays, they are intrinsically unable to discriminate between bona fide ICD induction and ICD-independent immunostimulation, as demonstrated for several commonly used anticancer agents 172 .”
Self-citationTumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling
Han, C., Liu, Z., Zhang, Y., Shen, A., Dong, C., Zhang, A., Moore, C., Ren, Z., Lu, C., Cao, X., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0641-5 · Cited by 162
Cascone, T., Kar, G., Spicer, J. D., García-Campelo, R., Weder, W., Daniel, D. B., Spigel, D. R., Hussein, M., Mazières, J., Oliveira, J., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0436 · Cited by 161
Programmed cell removal by calreticulin in tissue homeostasis and cancer
Feng, M., Marjon, K. D., Zhu, F., Weissman-Tsukamoto, R., Levett, A., Sullivan, K., Kao, K. S., Markovic, M., Bump, P. A., Jackson, H. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05211-7 · Cited by 160
Song, X., Zhou, Z., Li, H., Xue, Y., Lu, X., Bahar, İ., Kepp, O., Hung, M., Kroemer, G., & Wan, Y. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0402 · Cited by 160
Self-citationTargeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 160
Self-citationStanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance
Lin, H., Kryczek, I., Li, S., Green, M. D., Ali, A., Hamasha, R., Wei, S., Vatan, L., Szeliga, W., Grove, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.023 · Cited by 159
Role of the microbiota in response to and recovery from cancer therapy
Blake, S. J., Wolf, Y., Boursi, B., & Lynn, D. J. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00951-0 · Cited by 158
The oncolytic peptide LTX-315 triggers immunogenic cell death
Zhou, H., Forveille, S., Sauvat, A., Yamazaki, T., Senovilla, L., Ma, Y., Liu, P., Yang, H., Bezu, L., Müller, K., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.47 · Cited by 157
Self-citationBortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation
Gullà, A., Morelli, E., Samur, M., Botta, C., Hideshima, T., Bianchi, G., Fulciniti, M., Malvestiti, S., PRABHALA, R. H., Talluri, S., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0047 · Cited by 156
Oncolysis without viruses — inducing systemic anticancer immune responses with local therapies
Kepp, O., Marabelle, A., Zitvogel, L., & Kroemer, G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0272-7 · Cited by 154
Self-citationRodriguez-Ruiz, M. E., Buqué, A., Hensler, M., Chen, J., Bloy, N., Petroni, G., Sato, A., Yamazaki, T., Fucikova, J., & Galluzzi, L. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1655964 · Cited by 147
Self-citationSecreted gelsolin inhibits DNGR-1-dependent cross-presentation and cancer immunity
Giampazolias, E., Schulz, O., Lim, K. H. J., Rogers, N. C., Chakravarty, P., Srinivasan, N., Gordon, O., Cardoso, A., Buck, M. D., Poirier, E. Z., et al. (2021) · Cell · doi:10.1016/j.cell.2021.05.021 · Cited by 141
Advancing CAR T cell therapy through the use of multidimensional omics data
Yang, J., Chen, Y., Jing, Y., Green, M. R., & Han, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00729-2 · Cited by 135
Oca, R. M. D., Alavi, A., Vitali, N., Bhattacharya, S., Blackwell, C., Patel, K. J., Seestaller‐Wehr, L., Kaczynski, H., Shi, H., Dobrzynski, E., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0035 · Cited by 132
Self-citationImmunosuppression by Mutated Calreticulin Released from Malignant Cells
Liu, P., Zhao, L., Loos, F., Marty, C., Xie, W., Martins, I., Lachkar, S., Qu, B., Waeckel-Énée, E., Plo, I., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.11.004 · Cited by 130
Self-citationThibaudin, M., Fumet, J.-D., Chibaudel, B., Bennouna, J., Borg, C., Martin-Babau, J., Cohen, R., Fonck, M., Taïeb, J., Limagne, E., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02497-z · Cited by 125
Trial Watch—Oncolytic viruses and cancer therapy
Pol, J. G., Buqué, A., Aranda, F., Bloy, N., Cremer, I., Eggermont, A. M. M., Erbs, P., Fucikova, J. P., Galon, J., Limacher, J., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1117740 · Cited by 123
Self-citationDyck, L., Prendeville, H., Raverdeau, M., Wilk, M. M., Loftus, R. M., Douglas, A., McCormack, J., Moran, B., Wilkinson, M., Mills, E. L., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20210042 · Cited by 122
Pahl, J. H. W., Ruslan, S. E. N., Buddingh, E. P., Santos, S. J., Szuhai, K., Serra, M., Gelderblom, H. A. J., Hogendoorn, P. C. W., Egeler, R. M., Schilham, M. W., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2277 · Cited by 121
Ladoire, S., Enot, D., Senovilla, L., Ghiringhelli, F., Poirier-Colame, V., Chaba, K., Semeraro, M., Chaix, M., Penault-Llorca, F., Arnould, L., et al. (2016) · Autophagy · doi:10.1080/15548627.2016.1154244 · Cited by 117
Self-citationCellular cytotoxicity is a form of immunogenic cell death
Minute, L., Teijeira, Á., Sánchez-Paulete, A. R., Ochoa, M. C., Álvarez, M., Otano, I., Etxeberría, I., Bolaños, E., Azpilikueta, A., Garasa, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000325 · Cited by 115
Yamazaki, T., Pitt, J. M., Vétizou, M., Marabelle, A., Flores, C., Rekdal, Ø., Kroemer, G., & Zitvogel, L. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.35 · Cited by 106
Self-citationImmunogenic cell death: The cornerstone of oncolytic viro-immunotherapy
Palanivelu, L., Liu, C., & Lin, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1038226 · Cited by 106
Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress
Humeau, J., Sauvat, A., Cerrato, G., Xie, W., Loos, F., Iannantuoni, F., Bezu, L., Lévesque, S., Paillet, J., Pol, J. G., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911622 · Cited by 103
Self-citationObesity diminishes response to PD-1-based immunotherapies in renal cancer
Boi, S. K., Orlandella, R. M., Gibson, J. T., Turbitt, W. J., Wald, G., Thomas, L. J., Rosean, C. B., Norris, K. E., Bing, M. T., Bertrand, L. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000725 · Cited by 102
Extracorporeal photochemotherapy induces bona fide immunogenic cell death
Tatsuno, K., Yamazaki, T., Hanlon, D. J., Han, P., Robinson, E., Sobolev, O., Yurter, A., Rivera-Molina, F. E., Arshad, N., Edelson, R. L., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1819-3 · Cited by 97
Self-citationPhosphorylation of eukaryotic initiation factor-2α (eIF2α) in autophagy
Humeau, J., Leduc, M., Cerrato, G., Loos, F., Kepp, O., & Kroemer, G. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2642-6 · Cited by 97
Self-citationLim, E. A., Bendell, J. C., Falchook, G. S., Bauer, T. M., Drake, C. G., Choe, J. H., George, D. J., Karlix, J. L., Ulahannan, S. V., Sachsenmeier, K. F., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0612 · Cited by 96
Nicholas, R. A. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12601-6 · Cited by 93
Jaime‐Sánchez, P., Uranga-Murillo, I., Aguiló, N., Khouili, S. C., Arias, M. A., Sancho, D., & Pardo, J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000528 · Cited by 92
Røssevold, A. H., Andresen, N. K., Bjerre, C. A., Gilje, B., Jakobsen, E. H., Raj, S. X., Falk, R. S., Russnes, H. G., Jahr, T., Mathiesen, R. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02126-1 · Cited by 89 · cited 1×
“Moreover, induction therapy with ICD-inducing chemotherapeutics has been shown to sensitize malignant lesions to ICIs that target PDL1 or its receptor programmed cell death protein 1 (PDCD1, also known as PD1) 15,18,19 .”
Lévesque, S., Le Naour, J., Pietrocola, F., Paillet, J., Kremer, M., Castoldi, F., Baracco, E. E., Wang, Y., Vacchelli, E., Stoll, G., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1657375 · Cited by 86
Self-citationTargeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides
Vitale, I., Yamazaki, T., Wennerberg, E., Sveinbjørnsson, B., Rekdal, Ø., Demaria, S., & Galluzzi, L. (2021) · Trends in cancer · doi:10.1016/j.trecan.2020.12.012 · Cited by 84
Self-citationQuerfeld, C., Thompson, J. A., Taylor, M. H., DeSimone, J., Zain, J. M., Shustov, A. R., Johns, C., McCann, S. A., Lin, G. H. Y., Petrova, P. S., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00271-4 · Cited by 84
The integrated stress response in cancer progression: a force for plasticity and resistance
Lines, C. L., McGrath, M. J., Dorwart, T. J., & Conn, C. S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1206561 · Cited by 84
Wu, Q., Tian, A.-L., Li, B., Leduc, M., Forveille, S., Hamley, P., Galloway, W., Xie, W., Liu, P., Zhao, L., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002722 · Cited by 83 · cited 1×
“In line with this notion, autophagy inhibition downstream of insulin-like growth factor 1 receptor (IGF1R) hyperactivation is a poor prognostic marker coupled with signs of deficient immunosurveillance in breast cancer 130 .”
Self-citationThompson, E. A., & Powell, J. D. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-060619-023155 · Cited by 83
First Oncolytic Viral Therapy for Melanoma
Poh, A. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2015-158 · Cited by 79
Nanoparticle-based drug delivery systems to enhance cancer immunotherapy in solid tumors
Zhang, J., Wang, S., Zhang, D. D., He, X., Wang, X., Han, H., & Qin, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1230893 · Cited by 79
Zhao, L., Liu, P., Mao, M., Zhang, S., Bigenwald, C., Dutertre, C., Lehmann, C. H. K., Pan, H., Paulhan, N., Amon, L., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1338 · Cited by 78
Self-citationChiappori, A., Creelan, B., Tanvetyanon, T., Gray, J. E., Haura, E. B., Thapa, R., Barlow, M. L., Chen, Z., Chen, D., Beg, A. A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2742 · Cited by 75
Liu, L., Li, S., Qu, Y., Bai, H., Pan, X., Wang, J., Wang, Z., Duan, J., Zhong, J., Wan, R., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101206 · Cited by 71
Treatment of osteosarcoma with microwave thermal ablation to induce immunogenic cell death
Yu, Z., Geng, J., Zhang, M., Zhou, Y., Fan, Q., & Chen, J. (2014) · Oncotarget · doi:10.18632/oncotarget.2310 · Cited by 67
A Balancing Act: p53 Activity from Tumor Suppression to Pathology and Therapeutic Implications
Wang, M., & Attardi, L. D. (2021) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-042320-025840 · Cited by 66
Inhibition of the Adenosinergic Pathway in Cancer Rejuvenates Innate and Adaptive Immunity
Azambuja, J. H., Ludwig, N., Braganhol, E., & Whiteside, T. L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225698 · Cited by 65
Campbell, M. T., Matin, S. F., Tam, A. L., Sheth, R. A., Ahrar, K., Tidwell, R. S. S., Rao, P., Karam, J. A., Wood, C. G., Tannir, N. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26415-4 · Cited by 65
Giglio, P., Gagliardi, M., Tumino, N., Antunes, F., Smaili, S. S., Cotella, D., Santoro, C., Bernardini, R., Mattei, M., Piacentini, M., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1466765 · Cited by 63
Ventura, A., Vassall, A. N., Robinson, E., Filler, R. B., Hanlon, D. J., Meeth, K. M., Ezaldein, H. H., Girardi, M., Sobolev, O., Bosenberg, M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0171 · Cited by 59
FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma
Baines, A. C., Ershler, R., Kanapuru, B., Xu, Q., Shen, G., Li, L., Ma, L., Okusanya, Ó. O., Simpson, N. E., Nguyen, W., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0618 · Cited by 59
Bodywide ecological interventions on cancer
Kroemer, G., McQuade, J. L., Mérad, M., André, F., & Zitvogel, L. (2023) · Nature Medicine · doi:10.1038/s41591-022-02193-4 · Cited by 57
Self-citationA TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency
Naour, J. L., Liu, P., Zhao, L., Adjemian, S., Sztupinszki, Z. M., Taïeb, J., Mulot, C., Silvin, A., Dutertre, C., Ginhoux, F., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0465 · Cited by 56
Self-citationVedunova, M. V., Turubanova, V. D., Vershinina, O., Saviuk, M. O., Efimova, I., Mishchenko, T. A., Raedt, R., Vral, A., Vanhove, C., Korsakova, D., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05514-0 · Cited by 50
Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib
Scirocchi, F., Napoletano, C., Pace, A., Koshkaki, H. R., Filippo, A. D., Zizzari, I. G., Nuti, M., & Rughetti, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.755433 · Cited by 48
Contribution of annexin A1 to anticancer immunosurveillance
Baracco, E. E., Stoll, G., Endert, P. V., Zitvogel, L., Vacchelli, E., & Kroemer, G. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1647760 · Cited by 47
Self-citationLTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells
Yamazaki, T., Wennerberg, E., Hensler, M., Buqué, A., Kraynak, J., Fucikova, J. P., Zhou, X. K., Sveinbjørnsson, B., Rekdal, Ø., Demaria, S., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1962592 · Cited by 44
Self-citationA recombinant oncolytic Newcastle virus expressing MIP-3α promotes systemic antitumor immunity
Huang, F., Wang, J., Dai, S.-Z., Lin, Y., Sun, Y., Zhang, L., Lu, Z., Cao, R. Y., & Tan, G. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000330 · Cited by 42
Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia
Sugita, M., Yamazaki, T., Alhomoud, M., Martinet, J., Latouche, J., Golden, E. B., Boyer, O., van Besien, K., Formenti, S. C., Galluzzi, L., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05829-6 · Cited by 42
Self-citationXu, W., Liu, W., Yang, J., Lu, J., Zhang, H., & Ye, D. (2023) · Immunological Reviews · doi:10.1111/imr.13237 · Cited by 42
Improved antitumor immunity of chemotherapy in OSCC treatment by Gasdermin-E mediated pyroptosis
Mei, Z., Xingyu, C., Chen, Y., Xiaodong, S., Lv, S., & Wei, S. (2022) · APOPTOSIS · doi:10.1007/s10495-022-01792-3 · Cited by 40
Franz, S., Rennert, P., Woznik, M., Grützke, J., Lüdde, A., Pais, E. M. A., Finsterbusch, T., Geyer, H., Mankertz, A., & Friedrich, N. (2017) · Journal of Virology · doi:10.1128/jvi.01037-17 · Cited by 37
Patel, S. P., Pakkala, S., Pennell, N. A., Reckamp, K. L., Lanzalone, S., Polli, A., Tarazi, J., & Robert-Vizcarrondo, F. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0034 · Cited by 34
Richter, C., Thieme, S., Bandola-Simon, J. M., Laugsch, M., Anastassiadis, K., & Brenner, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062621 · Cited by 31
Autophagy-mediated metabolic effects of aspirin
Castoldi, F., Humeau, J., Martins, I., Lachkar, S., Loew, D., Dingli, F., Durand, S., Enot, D., Bossut, N., Chery, A., et al. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-00365-0 · Cited by 27
Self-citationHinterberger, M., Giessel, R., Fiore, G., Gräbnitz, F., Bathke, B., Wennier, S. T., Chaplin, P. J., Melero, I., Suter, M., Lauterbach, H., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001586 · Cited by 27
Obesity modulates the immune macroenvironment associated with breast cancer development
Núñez-Ruiz, A., Sánchez-Brena, F., López-Pacheco, C. P., Acevedo-Dominguez, N. A., & Soldevila, G. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266827 · Cited by 27
van Helden, M. J. G., Zwarthoff, S. A., Arends, R. J., Reinieren-Beeren, I., Paradé, M., Driessen-Engels, L., de Laat-Arts, K., Damming, D., Santegoeds-Lenssen, E. W. H., van Kuppeveld, D., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006567 · Cited by 26
Zhang, S., Zhao, L., Guo, M., Liu, P., Li, S., Xie, W., Tian, A.-L., Pol, J. G., Chen, H., Pan, H., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006785 · Cited by 25
Self-citationA fluorescent biosensor-based platform for the discovery of immunogenic cancer cell death inducers
Kepp, O., Sauvat, A., Leduc, M., Forveille, S., Liu, P., Zhao, L., Bezu, L., Xie, W., Zitvogel, L., & Kroemer, G. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1606665 · Cited by 23
Self-citationWu, A., Niu, J., Hong, Z., Gu, L., Huang, Y., & Qiu, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1211114 · Cited by 22
Dodging the CTL response: viral evasion of Fas and granzyme induced apoptosis
Keckler, M. S. (2006) · Frontiers in bioscience · doi:10.2741/2096 · Cited by 19
Bausart, M., Rodella, G., Dumont, M., Učakar, B., Vanvarenberg, K., Malfanti, A., & Préat, V. (2023) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2023.102681 · Cited by 19
Tertiary lymphoid structures as hubs of antitumour immunity
Kinker, G. S., & Medina, T. D. S. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00626-x · Cited by 18
A genotype-phenotype screening system using conditionally immortalized immature dendritic cells
Zhao, L., Liu, P., Xie, W., Zhang, S., Thieme, S., Zitvogel, L., Kroemer, G., & Kepp, O. (2021) · STAR Protocols · doi:10.1016/j.xpro.2021.100732 · Cited by 17
Self-citationCultrara, C. N., Uhl, C., Kirby, K. W., Elrazaq, E. A., Zellander, A., Andrews, D. W., Scott, C., Galluzzi, L., Exley, M. A., & Zilberberg, J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006880 · Cited by 17
Self-citationSIRPα-specific monoclonal antibody enables antibody-dependent phagocytosis of neuroblastoma cells
Bahri, M., Kailayangiri, S., Vermeulen, S., Galopin, N., Rössig, C., Paris, F., Fougeray, S., & Birklé, S. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02968-7 · Cited by 16
Formyl peptide receptor-1 (FPR1) represses intestinal oncogenesis
Naour, J. L., Montégut, L., Pan, Y., Scuderi, S. A., Cordier, P., Joseph, A., Sauvat, A., Iebba, V., Paillet, J., Ferrere, G., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2237354 · Cited by 15
Self-citationWei, B. M., Hanlon, D. J., Khalil, D., Han, P., Tatsuno, K., Sobolev, O., & Edelson, R. L. (2020) · PubMed Central · Cited by 13
Prognostic significance of STING expression in solid tumor: a systematic review and meta-analysis
Kim, Y.-H., Cho, N.-Y., Jin, L., Jin, H. Y., & Kang, G. H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1244962 · Cited by 13
Rs867228 in FPR1 accelerates the manifestation of luminal B breast cancer
Carbonnier, V., Naour, J. L., Bachelot, T., Vacchelli, E., André, F., Delaloge, S., & Kroemer, G. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2189823 · Cited by 11
Self-citationDevelopment of a risk model to predict prognosis in breast cancer based on cGAS-STING-related genes
Chen, C., Wang, J., Dong, C., LIM, D. J., & Feng, Z. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1121018 · Cited by 9
Cited by
The hallmarks of cancer immune evasion
Galassi, C., Chan, T. A., Vitale, I., & Galluzzi, L. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.010 · Cited by 565
Self-citationAdvances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Zhu, L., Song, G., Zhang, W., Wu, Y., Chen, Y., Song, J., Wang, D., Li, G., Tang, B. Z., & Li, Y. (2025) · Nature Communications · doi:10.1038/s41467-025-57533-y · Cited by 63
Tang, Y., Pan, T., Pang, E., Zhao, S., Shen, X., Tan, Q., Zhu, P., He, D., Wang, B., Song, X., et al. (2025) · Small · doi:10.1002/smll.202407680 · Cited by 10
Lim, S.-K., Lin, W.-C., Pan, Y.-C., Huang, S.-W., Yu, Y.-A., Chang, C.-H., Hu, C.-M. J., Mou, C.-Y., & Mou, K. Y. (2026) · eLife · doi:10.7554/elife.107671.3
Metadata
- Authors
- Galluzzi, L., Guilbaud, E., Schmidt, D., Kroemer, G., & Marincola, F. M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2024-04-15
- Volume
- 23
- Issue
- 6
- Pages
- 445-460
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W4394812354
- Cited by
- 538
- References
- 201
- FWCI
- 23.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.